Jonathan Douxfils’ Post

View profile for Jonathan Douxfils, graphic

Board Director & Scientific Director - QUALIblood s.a. | Director of the Clinical Pharmacology and Toxicology Research Unit - University of Namur

🚨 New Publication on #E4 in collaboration with Fuji Pharma Co. Ltd., Estetra, QUALIblood and two leading medical centers in #JapanHamamatsu University School of Medicine and Tottori University Faculty of Medicine! We are excited to share our latest research on the impact of #Estetrol combined with #Drospirenone on blood coagulation and fibrinolysis in patients with endometriosis. This study provides valuable insights into the safety profile of E4-based treatments for managing #endometriosis. This multicenter study demonstrated that the combination of E4 and DRSP had a significantly lesser impact on coagulation and fibrinolysis compared to Ethinyl Estradiol-based treatments, highlighting a promising approach for safer therapeutic options. Many thanks to our partners at Fuji Pharma Co. Ltd., Estetra, QUALIblood and the teams at Hamamatsu University School of Medicine and Tottori University for their exceptional collaboration. Together, we aim to advance women's health and bring innovative treatments to patients worldwide. 🔗 Read the full study below ⬇️ Unité de Recherche en Pharmacologie Clinique et Toxicologie (URPC) - Namur Research Institute for Life Sciences (NARILIS) - Université de Namur #Research #Innovation #Endometriosis #WomensHealth #E4

To view or add a comment, sign in

Explore topics